Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference | ||
By: PR Newswire Association LLC. - 29 Feb 2024 | Back to overview list |
|
REDWOOD CITY, Calif., Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event. About Arcellx, Inc. Arcellx is also developing its dosable and controllable CAR T therapy, ARC-SparX, through two Phase 1 programs, ACLX-001 for rrMM and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X (Twitter) at @arcellx and LinkedIn. Forward-looking Statements Investors: Media: View original content to download multimedia:https://www.prnewswire.com/news-releases/arcellx-to-participate-at-the-td-cowen-44th-annual-health-care-conference-302076323.html SOURCE Arcellx, Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |